News of Note—CSL’s flu vaccine sales, Inovio and more

non
In this week's news of note, sales of CSL's Flucelvax quadrivalent flu shot were up 43%. (Pixabay)

Here is some other vaccine news of note for the week:

> Sales of CSL’s Flucelvax quadrivalent flu vaccine were up 43% for the six months leading up to December. Brisbane Times article

> Inovio and The Wistar Institute are collaborating on two vaccines against tuberculosis and malaria, with total grants of more than $4.6 million from the Bill & Melinda Gates Foundation and the NIH. Release

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

> Three crisis management experts analyzed Sanofi Pasteur’s response to the Dengvaxia situation in the Philippines. The Wall Street Journal commentary

> FDA Commissioner Scott Gottlieb, M.D., said his agency is working with the CDC to understand why protection offered by this year’s flu vaccine is less than optimal. Tweet

> To cope with flu vaccine shortage this year, Hong Kong health officials are considering using shots intended for the southern hemisphere. South China Morning Post article

Suggested Articles

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.

Merck just last month won the world's first licensure for an Ebola vaccine. Now, an international group authorized funding to establish a stockpile.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.